Views & Analysis Is Europe ready for a single health technology assessment? The EU has unveiled plans for greater Health Technology Assessment harmonisation this week - and put the potential benefits for life sciences centre stage.
Views & Analysis Patient involvement in HTA Considering the essential role of patient experience in HTA and the role of pharma.
Views & Analysis The honest broker in market access Eric Low shares his views on why hurdles remain to new drug access.
Views & Analysis Mind the (implementation) gap Examining the true impact of a positive health technology assessment (HTA).
Views & Analysis Orphan drugs: overcoming barriers to market access What manufacturers should consider, after successfully overcoming any HTA hurdles, to achieve market access.
Views & Analysis Orphan drugs: overcoming HTA barriers to access How can orphan drug manufacturers demonstrate value and improve access to drugs?
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.